Get the Stockscreener App
32.91
1.38%
-0.46
After Hours:
32.87
-0.04
-0.12%
Rigel Pharmaceuticals stock is traded at $32.91, with a volume of 972.70K.
It is down -1.38% in the last 24 hours and up +15.03% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
See More
Previous Close:
$33.37
Open:
$33.99
24h Volume:
972.70K
Relative Volume:
2.63
Market Cap:
$608.90M
Revenue:
$299.77M
Net Income/Loss:
$364.23M
P/E Ratio:
1.7579
EPS:
18.7211
Net Cash Flow:
$79.27M
1W Performance:
+2.59%
1M Performance:
+15.03%
6M Performance:
-21.21%
1Y Performance:
+69.99%
1-Day Range:
$32.42
$34.15
1-Week Range:
$31.80
$34.39
52-Week Range:
$18.14
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
32.91 | 608.90M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Liquidity Mapping Around (RIGL) Price Events - Stock Traders Daily
Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rigel Pharmaceuticals secures rights to develop and market VEPPANU under new agreement - Traders Union
Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Institutional Confidence - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rigel Pharmaceuticals (RIGL) Secures Global Rights for Breast Ca - GuruFocus
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal - MSN
Rigel closes license deal for breast cancer drug VEPPANU, plans commercial launch in August - Pluang
Pfizer trades up with Rigel’s Veppanu deal done - TechStock²
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv - Bitget
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) - PR Newswire
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rigel Pharmaceuticals (RIGL) Advances 2.13%: Testing Resistance at $32.26Leveraged ETF Flow - newsline.com
RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart - ChartMill
Why (RIGL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Rigel Pharmaceuticals Edges Higher: Testing Key Resistance at $31.61Gap Up Stocks - newsline.com
Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals - Benzinga
Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes - Stock Titan
Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations - Stock Titan
Rigel (RIGL) CMO uses 850 shares to cover stock tax liability - Stock Titan
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations - Stock Titan
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
Rigel Pharmaceuticals Gains Momentum, Testing Key Resistance at $32.14Straddle Setup - newsline.com
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar - GuruFocus
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Pharmaceuticals Inc (RIGL) - GuruFocus
Understanding Momentum Shifts in (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade - Stock Titan
Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines - Yahoo Finance
Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference - GuruFocus
Rigel Pharmaceuticals to Present at Jefferies Global Healthcare Conference on May 27, 2026 - geneonline.com
Rigel (RIGL) Gains Momentum as Kissei Submits NDA for Rezlidhia in Japan - GuruFocus
Rigel Pharmaceuticals (RIGL) Gains Nearly 2% as Stock Tests Key Resistance Near $31.24High Reward Trades - thelegaladvocate.com
Rigel Pharmaceuticals Acquires Global Rights to Veppanu in $85 Million Deal, Targeting ESR1-Mutated Breast Cancer - geneonline.com
Biotech CEO to give Rigel company overview at Jefferies healthcare conference - Stock Titan
Rigel to Present at the Jefferies Global Healthcare Conference – Company Announcement - Financial Times
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
RIGL Technical Analysis | Trend, Signals & Chart Patterns | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress - PR Newswire
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):